Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Considerations for 3D Spheroid Formation and Imaging

Drastic differences in the ways cells behave and respond to drugs are observed when cells are cultured using 3D instead of 2D approaches. These differences are driving the adoption of more advanced cell culture models. With the added benefits of 3D cell cultur

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Drastic differences in the ways cells behave and respond to drugs are observed when cells are cultured using 3D instead of 2D approaches. These differences are driving the adoption of more advanced cell culture models. With the added benefits of 3D cell culture systems come additional challenges in terms of optimization, handling, and assaying. Here, we discuss a number of these obstacles and recommend how they may be addressed.

Spheroid formation

Optimizing the spheroid seeding density, media formulation, or culture period, or adding an overlay of Corning Matrigel® matrix, can lead to tighter spheroid formation.

Spheroid size

Spheroid size is determined by the cell type, seeding density, and culture time. As the spheroid becomes larger, it becomes more difficult for nutrients and oxygen to reach the center of the spheroid, which can lead to a hypoxic core. Depending on the assay, this may or may not be desirable. Optimizing the seeding density will play a very large role in the ability of the spheroids to initially form, as well as determine how long the spheroids can be kept in culture.

Media formulation

Media formulation may affect spheroid formation, and options should be tested with each cell type. Supplements, such as methylcellulose, can increase the viscosity of the medium and have been shown to aid in spheroid formation.

Time to form spheroid

Some cells will readily form spheroids within hours, while other cells will require several days. Monitoring spheroid formation over time will help in determining the ideal culture period for each application (Figure 1).

Spheroid handling

Media and buffer exchanges

Media and buffer exchanges can be challenging when working with spheroids. The process can be time consuming and pose a risk of losing or disturbing spheroids.

Corning spheroid microplates are automation friendly and make media and buffer exchanges easier to accomplish without the risk of disturbing the spheroid. For manual exchanges, we recommend careful pipetting to remove most of the medium in the well, ensuring pipette tips do not scratch the bottoms or sides of the wells. At least 10- to 20-µL residual volume should be left behind to avoid disrupting the spheroids. It is also possible to do half changes of medium more frequently instead of full exchanges.

The BioTek MultiFlo™ FX is an automated multimode reagent dispenser for 6- to 1536-well microplates. When equipped with BioTek’s AMX™ automated media exchange module, the dispenser can provide gentle aspiration and dispensing of media for 3D cell culture. Figure 2 compares spheroid loss from manual versus automated media exchanges. A significant number of spheroids were lost during manual exchanges, as denoted by the columns outlined in red; none were lost using the automated and highly efficient MultiFlo FX system.

Spheroid transfer

Spheroids can be removed from the spheroid microplates using Corning’s Axygen® wide-bore (1–200 µL) tips (Corning Cat. No. TF-205-WB-R-S) or a Corning 5-mL Stripette™. This can be helpful for spheroid-embedding protocols, neurogenesis assays, or any other application in which the spheroids need to be removed from the spheroid microplate.

Centrifugation

Cells seeded in the spheroid microplate can be centrifuged briefly at 300 × g to aid in spheroid formation or centering spheroids when an extracellular matrix is required.

Removal of spheroids from matrix

For applications that require the spheroid to be embedded in Corning Matrigel® matrix, there are several options to recover the spheroid from the matrix. One option is to reduce the temperature of the microplate to liquefy the matrix so that the spheroid can be removed. Another option, depending on the concentration of the matrix, is to add a cold buffer or medium to the well to dilute/liquefy the Matrigel matrix. This may need to be repeated to free the spheroid. Additionally, Corning Cell Recovery Solution (Corning Cat. No. 354253) may be used. It depolymerizes the Matrigel matrix and can be used to recover the spheroids.

Single-cell recovery

For assays requiring single-cell suspensions, spheroids can be dissociated by incubating with reagents such as Corning Accutase®; 5 mM EDTA; 1× trypsin/EDTA; or 1×, 5×, or 10× TrypLE™.

Spheroid assays

The black sidewalls and clear bottom of the spheroid microplate make it an ideal option for numerous fluorescent, luminescent, and colorimetric assays that can be conducted directly in the spheroid microplate. Depending on the size of the spheroid, it may become difficult for some assay reagents to penetrate fully. Therefore, optimization of each assay is recommended using appropriate positive and negative controls.

Homogenous assays

There are several commercially available 3D-specific reagents that have been optimized for use with spheroids. We recommend CellTiter-Glo® 3D cell viability assay (Promega Cat. No. G9683) for enumerating total ATP content of spheroids.

Imaging 3D cultures

Because the spheroid is significantly smaller than the microwell in which it resides, it is critical to understand where the signal is coming from in the well—whether it is a concentrated area or multiple areas within the well. A plate reader is designed to capture as much light from each well as possible, and with spheroids, a pinpoint of light will get lost in the background. Fortunately, with microscopy and image analysis, the field of view can be limited to mostly the spheroid and avoid background coming from the well.

Staining a 3D structure may require protocol optimization compared to the 2D equivalent. In general, the larger and tighter the spheroid, the longer and more complex it will be for complete staining to occur. If cell permeabilization is required, reagent choice and length of incubation time may need to be considered. We have had success using a variety of stains, including primary and secondary conjugated antibodies, with cells cultured in the spheroid microplate. You can also prelabel cells prior to seeding in the spheroid microplate or use fluorescent-protein-expressing cells to ensure that all cells are labeled as needed for the application.

The thickness of 3D cultures also necessitates the ability to image through the structure. The imaging system must be capable of z-stacking—in which the focal height can be changed and a series of images can be taken through the spheroid. A series of z-stacks through the biology can then be assembled into a composite using software algorithms to keep the in-focus portions of the image and reject the out-of-focus portions (Figure 3).

RFP-Fibroblast aggregated into a spheroid, then encased in Matrigel.

Overlaid brightfield and fluorescent images derived from a projection of a 20-slice z-stack, before (left image) and after (right image) a five-day incubation period (BioTek Cytation™ 5).

There is growing interest in adopting 3D culture approaches in drug discovery. Advanced technologies and guidelines for developing and culturing 3D models are increasingly available, making this approach more feasible, efficient, and automated.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →